We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Syndax (SNDX) Moves 10.7% Higher: Will This Strength Last?
Read MoreHide Full Article
Syndax Pharmaceuticals (SNDX - Free Report) shares soared 10.7% in the last trading session to close at $14.86. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 20.2% loss over the past four weeks.
Earlier this week, the company announced positive interim data from the phase I dose escalation portion of the phase I/II AUGMENT-101 study which is evaluating its oral menin inhibitor, SNDX-5613 in patients with mixed lineage leukemia rearranged and nucleophosmin (NPM1c) mutant relapsed/refractory acute leukemias. This might have been driving the rally.
Price and Consensus
This biopharmaceutical company is expected to post quarterly loss of $0.64 per share in its upcoming report, which represents a year-over-year change of -14.3%. Revenues are expected to be $0.5 million, up 31.6% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Syndax, the consensus EPS estimate for the quarter has been revised 11.1% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on SNDX going forward to see if this recent jump can turn into more strength down the road.
Image: Bigstock
Syndax (SNDX) Moves 10.7% Higher: Will This Strength Last?
Syndax Pharmaceuticals (SNDX - Free Report) shares soared 10.7% in the last trading session to close at $14.86. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 20.2% loss over the past four weeks.
Earlier this week, the company announced positive interim data from the phase I dose escalation portion of the phase I/II AUGMENT-101 study which is evaluating its oral menin inhibitor, SNDX-5613 in patients with mixed lineage leukemia rearranged and nucleophosmin (NPM1c) mutant relapsed/refractory acute leukemias. This might have been driving the rally.
Price and Consensus
This biopharmaceutical company is expected to post quarterly loss of $0.64 per share in its upcoming report, which represents a year-over-year change of -14.3%. Revenues are expected to be $0.5 million, up 31.6% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Syndax, the consensus EPS estimate for the quarter has been revised 11.1% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on SNDX going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>